Chronic Pain in COVID-19 Patients Discharged From Intensive Care Unit

Status Completed

Clinical Trial Summary

More than six million French were affected by SARS-COV2 epidemic. About 20% of infected peoples were hospitalized, and about 5% were admitted to the intensive care units (ICU) for severe SARS-COV2 acute respiratory distress syndrome (ARDS) management. A spectrum of neuropsychiatric sequelae, specific for the ICU exposure, was already described, including post-intensive care syndrome and persistent pain. A growing body of evidence suggests the impact of SARS-COV2 exposure on the occurrence of neurological disorders and chronic pain syndrome development in COVID-19 patients. Taking together, one can expect a large number of patients discharged from ICU after severe COVID-19 with high prevalence of persistent pain and psychological disorders. To date, no study has evaluated neither the incidence of persistant pains in ICU COVID-19 survivors, nor pain phenotypes. The knowledge of such data is crucial in order to anticipate the management of such patients by specialized pain team, and to quantify the possible incurred burden of care. Our study aims to evaluate the incidence of pain, pain localization and severity, associated pain-related psychological disorders, and to perform quantitative sensory testing in severe COVID-19 patients, admitted to the ICU for more than 48 hours and successfully discharged home during the first French pandemic wave.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04940208
Study type	Observational
Source	Hôpital de la Croix-Rousse
Contact
Status	Completed
Phase
Start date	January 11, 2021
Completion date	February 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04699734` - Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy	N/A
Recruiting	`NCT06019325` - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy	N/A
Completed	`NCT05235191` - Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies	Phase 3
Completed	`NCT05845177` - Persistent Pain After Hip Replacement
Completed	`NCT05496205` - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers	Phase 1
Not yet recruiting	`NCT05949554` - Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
Withdrawn	`NCT05052645` - Ear Acupuncture for Neuropathic Pain	N/A
Completed	`NCT02930551` - Neuromas as the Cause of Pain	N/A
Completed	`NCT02824588` - Working Memory Training for Chronic Neuropathic and Fibromyalgia Pain	N/A
Completed	`NCT02866396` - Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement
Active, not recruiting	`NCT02560545` - Cannabinoids Effects on the Pain Modulation System	N/A
Enrolling by invitation	`NCT02485795` - Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management	N/A
Not yet recruiting	`NCT02246517` - The Effect of N2O on Chronic Neuropathic Pain Patients	Phase 0
Completed	`NCT02099890` - The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury	Phase 3
Completed	`NCT01946555` - Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain	N/A
Completed	`NCT01884662` - Virtual Walking for Neuropathic Pain in Spinal Cord Injury	N/A
Completed	`NCT01718821` - Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients	N/A
Completed	`NCT01669967` - The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin	N/A
Completed	`NCT01201317` - A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy	Phase 2
Completed	`NCT01207596` - Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain	Phase 4